SG Power Plans 300% Rights Issue to Raise Rs534 Million for Healthcare Pivot

SG Power Limited, a small Karachi based electricity producer, set out a plan to change what kind of company it is. The board approved a large right share issue to fund a move into healthcare and pharmaceuticals, a step that would take the company well away from its power generation roots.

What the SG Power rights issue changed

SG Power said on 18 May 2026 that its board had approved a 300 percent right share issue. That means about three new shares offered for every one share already held, a total of 53.49 million ordinary shares at the par value of Rs10 each. The issue is meant to raise more than Rs534 million. A rights issue lets a company sell new shares to existing holders to bring in fresh cash, and the size here is large relative to the company.

The stated purpose is the key part. Management said the money would go toward investments in healthcare and related businesses as part of a long term diversification and growth plan. The company described this as pursuing strategic opportunities within the healthcare industry, alongside strengthening its financial position and equity base. The plan still needs shareholders to vote it through and the Securities and Exchange Commission of Pakistan to clear it. Major shareholders and directors have committed to take up their share, and the rest is underwritten.

Why the move matters for power generation stocks

Pakistan's older thermal power producers face a difficult backdrop. Many run on furnace oil or gas, capacity payments and tariffs are under review, and circular debt keeps cash tied up across the chain. For a small producer like SG Power, which supplies an associated company, the economics of staying purely in power have narrowed. A pivot into healthcare is an attempt to put capital somewhere with better growth, helped by the strong run the listed pharmaceutical sector has had since drug pricing was deregulated.

The trade off is real. Raising capital equal to three times the existing share count brings in a lot of money but also a lot of new shares, which spreads ownership and earnings across a wider base. Moving into a new industry where the company has no track record adds execution risk on top of that. The plan signals ambition, but the value depends entirely on what the company actually buys or builds with the proceeds.

Which stocks, and why

This is a direct, company specific event for SG Power, and the read is genuinely mixed rather than clearly good or bad. A large rights issue plus a full change of business direction is material to the company's future shape, which is why the influence is high. The direction is best read as neutral for now, because the upside of cheaper capital and a faster growing sector sits against the dilution from new shares and the risk of entering healthcare cold.

What to watch

Watch whether shareholders approve the issue and whether the SECP clears it, since neither is guaranteed. Track how much of the Rs534 million is actually raised and, more importantly, what the company does with it, the specific healthcare assets or partnerships it names. Watch the takeup rate of the rights, the pricing of any acquisition, and whether management sells or winds down the existing power operations as it shifts focus.